• Wall Street NY 10005, USA
  • contact@zenithpublications.org

Home

Oncology Innovation & Therapeutics

Journal Cover
PMC Abbreviation Oncol Innov Ther
ISSN Number XXXX-XXXX
Prefix DOI 10.67375/OncolInnovTher
Peer Review Double-Blind
Current Volume Volume 1
Manuscript Processing 28–35 Days (After Submission)
Publication Model Open Access
Year of Inaugural Volume 2026
Contact Email contact@zenithpublications.org
Language English

About Journal

Oncology Innovation & Therapeutics is a peer-reviewed, open-access journal committed to advancing research, clinical innovation, and therapeutic development in oncology. The journal offers a global platform for publishing original investigations, systematic reviews, translational studies, biomarker development, clinical trials, and technology-enabled therapeutic strategies that tackle cancer at molecular, cellular, and system levels.

Our mission is to accelerate the translation of cutting-edge cancer science into effective patient-centred therapies, while promoting data-driven innovation, interdisciplinary collaboration, and global access. We invite contributions from oncologists, cancer biologists, translational scientists, biomedical engineers, data scientists, and healthcare system innovators. The journal is dedicated to rigorous peer review, transparent publishing, and wide dissemination to enhance cancer care outcomes worldwide.

Recent Articles

Research Article

From Treatment Delivery to Knowledge Generation: A Decade of RTT-Led Evidence and Research Culture in Radiotherapy: A Narrative Review

Abstract: Introduction: Radiation therapy has evolved substantially in recent years, with Radiation Therapists and Therapeutic radiographers (RTTs) expanding beyond technical roles...

Read Full Article →
Original Research Article

Targeting Metabolism and Disulfidptosis: A Novel strategy for Cancer Therapy

Abstract: Disulfidptosis represents a recently characterized form of programmed cell death driven by an intracellular imbalance between cystine and the vital reductant...

Read Full Article →